荣昌生物大幅回调逾20%!泰它西普授权给美国Vor Bio公司,首付款4500万美元

老虎资讯综合
26 Jun

6月26日,荣昌生物大幅回调逾20%!泰它西普授权给美国Vor Bio公司,首付款4500万美元。

荣昌生物今早宣布,将公司具有自主知识产权的泰它西普有偿许可给美国纳斯达克上市公司Vor Bio,Vor Bio将获得泰它西普在除大中华区以外的全球范围内开发、生产和商业化的独家权利;荣昌生物将取得Vor Bio价值1.25亿美元现金及认股权证(包括4500万美元的首付款和价值8000万美元的认股权证,认股权证可以每股0.0001美元认购Vor Bio 3.2亿股的普通股,约占Vor Bio经扩大总发行股本的23%)、最高可达41.05亿美元的里程碑付款,总金额42.3亿美元,此外荣昌生物还将收到高个位数至双位数销售提成款。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10